Kissei Pharmaceutical Co., Ltd. 4547.T Stock
Kissei Pharmaceutical Co., Ltd. Price Chart
Kissei Pharmaceutical Co., Ltd. 4547.T Financial and Trading Overview
Kissei Pharmaceutical Co., Ltd. stock price | 3145 JPY |
Previous Close | 2938 JPY |
Open | 2926 JPY |
Bid | 2947 JPY x 0 |
Ask | 2957 JPY x 0 |
Day's Range | 2925 - 2965 JPY |
52 Week Range | 2342 - 3125 JPY |
Volume | 226.1K JPY |
Avg. Volume | 65.38K JPY |
Market Cap | 137.06B JPY |
Beta (5Y Monthly) | 0.270114 |
PE Ratio (TTM) | 10.731707 |
EPS (TTM) | 246.57 JPY |
Forward Dividend & Yield | 82 (2.77%) |
Ex-Dividend Date | September 28, 2023 |
1y Target Est | 3283.3 JPY |
4547.T Valuation Measures
Enterprise Value | 88.29B JPY |
Trailing P/E | 10.731707 |
Forward P/E | 12.355406 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 2.030745 |
Price/Book (mrq) | 0.7011315 |
Enterprise Value/Revenue | 1.308 |
Enterprise Value/EBITDA | 29.768 |
Trading Information
Kissei Pharmaceutical Co., Ltd. Stock Price History
Beta (5Y Monthly) | 0.270114 |
52-Week Change | 23.39% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3125 JPY |
52 Week Low | 2342 JPY |
50-Day Moving Average | 2809 JPY |
200-Day Moving Average | 2603.92 JPY |
4547.T Share Statistics
Avg. Volume (3 month) | 65.38K JPY |
Avg. Daily Volume (10-Days) | 68.12K JPY |
Shares Outstanding | 46.12M |
Float | 39.93M |
Short Ratio | N/A |
% Held by Insiders | 25.87% |
% Held by Institutions | 25.09% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 80 |
Trailing Annual Dividend Yield | 2.72% |
5 Year Average Dividend Yield | 215.00% |
Payout Ratio | 0.2456 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | March 31, 2023 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | March 31, 2024 |
Profitability
Profit Margin | 15.59% |
Operating Margin (ttm) | -1.69% |
Gross Margin | 47.96% |
EBITDA Margin | 4.39% |
Management Effectiveness
Return on Assets (ttm) | -0.31% |
Return on Equity (ttm) | 5.35% |
Income Statement
Revenue (ttm) | 67.49B JPY |
Revenue Per Share (ttm) | 1463.56 JPY |
Quarterly Revenue Growth (yoy) | 3.69% |
Gross Profit (ttm) | 32.38B JPY |
EBITDA | 2.97B JPY |
Net Income Avi to Common (ttm) | 10.53B JPY |
Diluted EPS (ttm) | 274.7 |
Quarterly Earnings Growth (yoy) | -36.70% |
Balance Sheet
Total Cash (mrq) | 49.6B JPY |
Total Cash Per Share (mrq) | 1075.54 JPY |
Total Debt (mrq) | 1.49B JPY |
Total Debt/Equity (mrq) | 0.77 JPY |
Current Ratio (mrq) | 6.729 |
Book Value Per Share (mrq) | 4204.632 |
Cash Flow Statement
Operating Cash Flow (ttm) | -6679000064 JPY |
Levered Free Cash Flow (ttm) | -7653875200 JPY |
Profile of Kissei Pharmaceutical Co., Ltd.
Country | Japan |
State | N/A |
City | Matsumoto |
Address | 19-48, Yoshino |
ZIP | 399-8710 |
Phone | 81 263 25 9081 |
Website | https://www.kissei.co.jp |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. Its products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. The company is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. Kissei Pharmaceutical Co., Ltd. was incorporated in 1946 and is headquartered in Matsumoto, Japan.
Q&A For Kissei Pharmaceutical Co., Ltd. Stock
What is a current 4547.T stock price?
Kissei Pharmaceutical Co., Ltd. 4547.T stock price today per share is 3145 JPY.
How to purchase Kissei Pharmaceutical Co., Ltd. stock?
You can buy 4547.T shares on the Tokyo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kissei Pharmaceutical Co., Ltd.?
The stock symbol or ticker of Kissei Pharmaceutical Co., Ltd. is 4547.T.
Which industry does the Kissei Pharmaceutical Co., Ltd. company belong to?
The Kissei Pharmaceutical Co., Ltd. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Kissei Pharmaceutical Co., Ltd. have in circulation?
The max supply of Kissei Pharmaceutical Co., Ltd. shares is 44.21M.
What is Kissei Pharmaceutical Co., Ltd. Price to Earnings Ratio (PE Ratio)?
Kissei Pharmaceutical Co., Ltd. PE Ratio is 12.75499800 now.
What was Kissei Pharmaceutical Co., Ltd. earnings per share over the trailing 12 months (TTM)?
Kissei Pharmaceutical Co., Ltd. EPS is 246.57 JPY over the trailing 12 months.
Which sector does the Kissei Pharmaceutical Co., Ltd. company belong to?
The Kissei Pharmaceutical Co., Ltd. sector is Healthcare.
Kissei Pharmaceutical Co., Ltd. 4547.T included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Developed ex US SC NTR G NQDMXUSSCGBPN | 1704.47 GBP 2179.91 USD |
0
|
— — | 1704.47 GBP 2179.91 USD | 1704.47 GBP 2179.91 USD | — - | — — |
- {{ link.label }} {{link}}